Acquisition by Nanavaty Maulik of 101276 shares of Rani Therapeutics subject to Rule 16b-3

RANI Stock  USD 2.02  0.03  1.51%   
Under 59% of all Rani Therapeutics' traders are looking to take a long position. The analysis of the overall investor sentiment regarding Rani Therapeutics Holdings suggests that some traders are interested. Rani Therapeutics' investing sentiment shows overall attitude of investors towards Rani Therapeutics Holdings.
  
Filed transaction by Rani Therapeutics Holding director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Rani insider trading alert for grant of stock option right to buy by Nanavaty Maulik, the corporate stakeholder, on 30th of May 2023. This event was filed by Rani Therapeutics Holding with SEC on 2023-05-30. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Rani Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Rani Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Rani Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Rani Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Rani Therapeutics Fundamental Analysis

We analyze Rani Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Beta

Beta Comparative Analysis

Rani Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Rani Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rani Therapeutics stock to make a market-neutral strategy. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics with similar companies.

Peers

Rani Therapeutics Related Equities

CABACabaletta Bio   26.91   
0%
100.0%
SRZNSurrozen   19.37   
0%
71.0%
GLUEMonte Rosa   13.72   
0%
50.0%
TNYATenaya Therapeutics   11.15   
0%
41.0%
LYRALyra Therapeutics   10.53   
0%
39.0%
MNPRMonopar Therapeutics   8.84   
0%
32.0%
VINCVincerx Pharma   7.69   
0%
28.0%
BMEABiomea Fusion   3.13   
0%
11.0%
VCNXVaccinex   2.44   
0%
9.0%
TRVITrevi Therapeutics   2.13   
0%
7.0%
PMVPPmv Pharmaceuticals   1.25   
0%
4.0%
MOLNMolecular Partners   0.17   
1.0%
0%
TARAProtara Therapeutics   0.99   
3.0%
0%
ALXOAlx Oncology   1.99   
7.0%
0%
TYRATyra Biosciences   2.00   
7.0%
0%
PHVSPharvaris   2.06   
7.0%
0%
EYPTEyepoint Pharmaceuticals   2.21   
8.0%
0%
CRVSCorvus Pharmaceuticals   3.50   
13.0%
0%
VIRXViracta Therapeutics   6.67   
24.0%
0%

Complementary Tools for Rani Stock analysis

When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios